FMP

FMP

Enter

XTLB - XTL Biopharmaceutica...

Balance sheet data of XTL Biopharmaceuticals Ltd.(XTLB), XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development

photo-url-https://financialmodelingprep.com/image-stock/XTLB.png

XTL Biopharmaceuticals Ltd.

XTLB

NASDAQ

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

2.29 USD

-0.24 (-10.48%)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep